Mapping the Genome of Chemoresistant Ovarian Cancer with Multi-Omic Profiling

June 22, 2022 2:00 p.m. - 3:00 p.m. ET

Register for the June Cancer Genomics Cloud (CGC) webinar where Dr. Michelle R. Jones of Cedars-Sinai Medical Center will discuss how she’s used the CGC to map the genome of chemoresistant ovarian cancer with multi-omic profiling.

Ovarian cancer is the most lethal gynecologic cancer, with most patients diagnosed at late stages and succumbing to the disease due to relapse and the development of chemoresistance. Paired primary (chemo-naive) and relapse ovarian cancer tumors were profiled for the first time in this study, revealing large scale conservation of gene regulation and expression throughout disease progression. Insights into the differences in homologous recombination deficient and proficient tumors implicate differing immune evasion pathways and novel candidates for further study.

As one of the three Cloud Resources within the NCI Cancer Research Data Commons (CRDC), the Seven Bridges’ CGC provides researchers access to a wide variety of data sets, a catalog of tools to analyze and visualize the data directly from the browser, and scalable computational resources to perform large scale analysis on the cloud.

Michelle R. Jones, Ph.D.

Dr. Jones is a research scientist in the Center for Bioinformatics and Functional Genomics at Cedars-Sinai Medical Center. Her lab works on projects that apply genomics methods to improve the understanding of inherited risk for ovarian cancer.

Vote below about this page’s helpfulness.

Enter the characters shown in the image.